Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Spyre Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Spyre Therapeutics, Inc.’s stock price such as:

• Spyre Therapeutics, Inc.’s current stock price and volume
• Why Spyre Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SYRE from analysts
• SYRE’s stock price momentum as measured by its relative strength

About Spyre Therapeutics, Inc. (SYRE)

Before we jump into Spyre Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Want to learn more about Spyre Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Spyre Therapeutics, Inc..

Spyre Therapeutics, Inc.’s Stock Price as of Market Close

As of January 15, 2026, 1:19 PM, CST, Spyre Therapeutics, Inc.’s stock price was $32.760.

Spyre Therapeutics, Inc. is down 1.21% from its previous closing price of $33.160.

During the last market session, Spyre Therapeutics, Inc.’s stock traded between $32.630 and $34.170. Currently, there are approximately 60.41 million shares outstanding for Spyre Therapeutics, Inc..

Spyre Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Spyre Therapeutics, Inc. Stock Price History

During the month of January, Spyre Therapeutics, Inc.’s stock price has not significantly increased or decreased. In order to understand the stock price forecast for Spyre Therapeutics, Inc., you may need to analyze their annual trend or other metrics instead.

Over the last year, Spyre Therapeutics, Inc. has hit prices as high as $35.310 and as low as $10.910. Year to date, Spyre Therapeutics, Inc.’s stock is down 0%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Spyre Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 14, 2026, there were 3 analysts who downgraded Spyre Therapeutics, Inc.’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Spyre Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Spyre Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Spyre Therapeutics, Inc. (SYRE) by visiting AAII Stock Evaluator.

Relative Price Strength of Spyre Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 14, 2026, Spyre Therapeutics, Inc. has a weighted four-quarter relative price strength of 18.40%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Spyre Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Spyre Therapeutics, Inc. Stock Price: Bottom Line

As of January 15, 2026, Spyre Therapeutics, Inc.’s stock price is $32.760, which is down 1.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Spyre Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.